Johnson & Johnson (JNJ) Revenue Up On Pfizer Unit Purchase
Johnson & Johnson’s (JNJ) revenue rose 13% to $15.1 billion in Q2. However, if revenue from the purchase of Pfizer’s consumer healthcare business was accounted for, the topline would have been up only 3.6%. Revenue at the company’s medical device…
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Johnson & Johnson’s (JNJ) revenue rose 13% to $15.1 billion in Q2. However, if revenue from the purchase of Pfizer’s consumer healthcare business was accounted for, the topline would have been up only 3.6%.
Revenue at the company’s medical device business was up 5.1%. Its pharma business rose 4.8%.
The company’s overall net margin fell slightly to 20.4%.
Douglas A. McIntyre
Contact [email protected] for any questions or corrections.


